Search Medical Condition
Please enter condition
Please choose location

Vandoeuvre cedex, France Clinical Trials

A listing of Vandoeuvre cedex, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (139) clinical trials

Surgery in Treating Patients With Neuroblastoma

OBJECTIVES: - Evaluate the safety and efficacy of surgical treatment alone for stage II neuroblastoma without N-myc amplification (NMA). - Describe predictive factors of relapse and survival for stages I and II neuroblastoma without NMA treated by surgery alone. OUTLINE: Patients with localized resectable tumors undergo surgery. Postoperative evaluations are ...

Phase

0.0 miles

Learn More »

Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer

OBJECTIVES: - Determine the 18-month survival rate of patients with metastatic renal cell carcinoma treated with allogeneic stem cell transplantation. - Determine the objective rate of response of patients treated with this regimen. - Determine post-transplant immunological reactions and recuperation of patients treated with this regimen. - Determine the antitumoral ...

Phase

0.0 miles

Learn More »

Folinic Acid in Children With Autism Spectrum Disorders

The aim of this study is to realise a pilot study in France in order to evaluate the efficiency of folinic acid in treatment of autism spectrum disorder and get first estimations about prevalence of auto antibodies anti-FRα in France. The study is a randomized controlled trial monocentric,evaluating folinic acid ...

Phase

0.0 miles

Learn More »

Bortezomib and Low Dose Cytarabine in the Treatment of High-Risk Myelodysplastic Syndromes

Four cycles of treatment are proposed at 28 day intervals in an ambulatory setting Cycle 1 : - Cytarabine 10 mg /m2/day subcutaneous injection for 14 days - Bortézomib 1,5mg/m2 days 1,4,8,11 Cycles 2, 3, 4 : - Cytarabine 20 mg /m2/j subcutaneous injections for 14 days - Bortézomib 1,5mg/m2 ...

Phase

0.0 miles

Learn More »

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

Subjects meeting all inclusion and exclusion criteria will receive lenalidomide lenalidomide will be administered at 10 mg (two 5 mg capsules) once daily on Days 1–21, every 4 weeks. Bone marrow aspirate (baseline and during the course of the study at week 8, 16, 32, 52 and when clinically indicated/for ...

Phase

0.0 miles

Learn More »

Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors

OBJECTIVES: - Compare progression-free survival rates of patients with poor prognosis stage II or III non-seminomatous germ cell tumors with an unfavorable decrease of tumor markers after treatment with 1 course of bleomycin, etoposide, and cisplatin followed by subsequent treatment with 3 additional courses of bleomycin, etoposide, and cisplatin OR ...

Phase

0.0 miles

Learn More »